Single-Dose CRISPR Therapy Significantly Reduces Hereditary Angioedema Attacks in Phase 3 Trial

A single infusion of lonvoguran ziclumeran, an investigational CRISPR-Cas9 therapy, demonstrated an 87% reduction in hereditary angioedema attacks compared to placebo in a Phase 3 trial. This significant finding, with 62% of patients remaining attack-free, offers a promising, potentially one-time, treatment for a rare and life-threatening genetic disorder.